Pharmacy

Quality and Complete project materials for all departments

DEVELOPMENT OF XANTHOHUMOL DERIVATIVES AS MILD MITOCHONDRIAL UNCOUPLERS FOR TREATMENT OF METABOLIC SYNDROME

Abstract

This report describes the development of xanthohumol derivatives as mild mitochondrial uncouplers for treatment of metabolic syndrome. The metabolic syndrome [3] comprises multiple risk factors for cardiovascular disease. It is clinically diagnosed by one or more of the following conditions: atherogenic dyslipidemia, elevated blood pressure, insulin resistance and/or glucose intolerance leading both to diabetes, proinflammatory state, prothrombotic state and abdominal obesity. Obesity [4] results from an energy imbalance where fuel intake is in excess compared to energy expenditure. Among the pharmacotherapeutic strategies to treat obesity, targeting mitochondrial uncoupling appears to be one of them, as mitochondria are the cellular source of energy. Xanthohumol (XN; 3'-[3,3-dimethyl allyl]-2',4',4-trihydroxy-6'-methoxychalcone), a major prenylated flavonoid from hops used for making beer, has shown anti-obesity effects by inducing a reduction in body weight gain in the Zucker rat model of obesity and metabolic syndrome. XN can increase energy expenditure by mild mitochondrial uncoupling [5]. However, some concerns have been expressed about the use of XN in dietary supplements [6], as 8prenylnaringenin (8-PN), one of its metabolites [7-9], is the most potent phytoestrogen known to date and since it can act as a weak agonist of estrogen receptors in the body [1012]. 8-PN is generated from XN

Material Code

PBM_qXB9I

Reference

Downloaded from Projectbasket.com.ng

Quality Material By Project Basket

Price

₦3,000

Get Complete Material Quick Download

 

Related Materials

Fetching comments. Please wait...